Jade Biosciences: Caution Advised Before Clinical Trial Results
Jade Biosciences is a pre-revenue biotech focused on JADE101 for IgA nephropathy, offering potential high potency and dosing advantages. I rate JBIO a Hold due to binary risk: success could increase the share price, but failure in key trials could cause …